In 2020, approximately 604,000 women were diagnosed with cervical cancer (CxCa), and 342,000 women died. Nearly 90% of CxCa-associated deaths occur in low- and middle-income countries (LMICs), where access to health services including screening and treatment remains limited. The World Health Organization (WHO) developed a global strategy to eliminate CxCa as a public health problem, which could result in >62 million lives saved by 2120. Strategy targets by 2030 include: 90% of adolescent girls receiving prophylactic HPV vaccine, 70% of women receiving twice-lifetime CxCa screening, and 90% of lesions treated. However, implementation lags behind strategy targets. The cost and complexity of HPV screening and treatment approaches may hamper scale-up, particularly for LMICs. Development of therapeutic HPV vaccines (TxV), designed to clear persistent high-risk HPV infection and/or cause CIN lesion regression, could aid in cervical cancer elimination. The potential value of TxV is highest if they can be developed and implemented quickly in addition to ongoing scale-up of existing interventions. To understand the full potential value of these vaccines, it is important to consider how they would be used and delivered within broader CxCa prevention programs, as well as the vaccine attributes that would optimize their public health impact. This 90-minute session will explore the potential for TxV to meet the global public health need, by reducing CxCa cases and deaths. Participants will gain an understanding of the potential public health value, scientific feasibility, future implementation considerations, and WHO preferred product characteristics.